Cytophage Develops Freeze-Dried Phage Tablets For Poultry

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.

Cytophage Technologies (TSXV: CYTO) has announced the launch of a simplified application option for its bacteriophages that it believes will set itself apart within the phage industry globally.

The company has developed a lyophilized phage tablet intended to treat multiple types of bacteria, including E. coli and Salmonella, throughout the lifecycle of poultry. The use of lyophilized phage tablets is providing an alternative to the liquid form that is presently used in the industry, which most often requires a cold chain.

Antimony Resources — sponsored Sponsored · Antimony Resources

”The importance of eliminating the need for a cold chain cannot be overstated. Offering phages in lyophilized form represents a competitive advantage over other phage producers who have only liquid products that require refrigeration. Our innovative manufacturing increases our products’ heat tolerance and shelf-life,” commented Dr Steven Theriault.

READ: Cytophage Enters Letter Of Intent With Major Singapore-Based Agrifood Company

The tablets are freeze dried and stabilized, which enable Cytophage’s phage products to be more easily used in hot climates such as Southeast Asia. The tablets are ready to use, dose controlled, and dissolve in water for application.

Development of the tablet is said to be a direct response to Cytophage working with the poultry industry on phage products that assist in reducing the use of broad-spectrum antibiotics, and replacing those antibiotics with target phages. The firm intends to leverage the new product format across its existing and pending product lines globally.

Cytophage Technologies last traded at $0.35 on the TSX Venture.


FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Silver Is in a New Price Regime, and the Market Isn’t Used to It | Keith Neumeyer – First Majestic

Agnico Eagle Just Made a Massive Gold Land Grab

A Copper-Gold Deposit Caught the White House’s Attention | Rob McLeod – Cambria Gold

Recommended

Mercado Drills 256 g/t Silver Over 6.5 Metres In First Drill Hole of Inaugural Program

Antimony Resources Drills 4.38% Sb Over 7.05 Metres At Bald Hill In Final Hole Of 2025 Program

Trending

Related News

Cytophage Enters Letter Of Intent With Major Singapore-Based Agrifood Company

Cytophage Technologies (TSXV: CYTO) is focusing its efforts on expanding the commercialization of its phage...
Friday, June 21, 2024, 08:45:08 AM

Cytophage: Landmark Phage Therapy Saves Ottawa Woman From Life-Threatening Infection

A 79-year-old resident from the Ottawa area credits an experimental treatment developed in Winnipeg with...
Wednesday, April 3, 2024, 07:56:00 AM

McDonald’s E.coli Crisis: This Canadian Biotech May Have The Solution | Cytophage with Steven Theriault

In this interview, Dr. Steven Theriault, CEO & Chief Science Officer of Cytophage Technologies (TSXV:...
Saturday, November 16, 2024, 09:13:00 AM

Cytophage Sees Its Bacteriophages Used As Treatment In Canada Under Single Subject Clinical Trial

For the first time in Canadian history, bacteriophage therapy is slated to be utilized to...
Friday, March 1, 2024, 10:14:56 AM

Phage Therapy’s Rising Demand: Cytophage at the Forefront with Dr. Steven Theriault

In this interview, Dr. Steven Theriault, CEO of Cytophage Technologies Ltd. (TSXV:CYTO), presents phage therapy...
Thursday, August 15, 2024, 02:04:00 PM